Viralytics raises $4.7m to fund melanoma trial
Tuesday, 20 December, 2011
Viralytics has announced it has raised $4.7 million in a share purchase plan, which has raised the company’s cash reserves to over $8 million.
The fund raising was undertaken to coincide with the commencement of patient enrolment in the company’s US-based phase II melanoma trial.
The issue price of the shares was 30.84c and was based on the five day volume weighted price as of 14 December.
Viraltyics’ (ASX:VLA) share price dropped 5.5% to 34c by mid-afternoon, down from 36c at Monday’s close.
argenx and Monash University partner against autoimmune diseases
To advance a pioneering molecule for autoimmune diseases, global immunology company argenx has...
Archer completes potassium sensing alpha prototype
Quantum technology company Archer Materials Limited has developed an early Biochip prototype...
Farm animals and aquaculture cryopreservation partnership announced
Vitrafy Life Sciences Limited has announced that it has entered a 12-month exclusive agreement...
